Biltricide Use In Pregnancy & Lactation

Animal studies have not indicated that treatment with Biltricide harms an unborn child. According to reports in the literature, a large number of women have been treated to date without harmful effects.
The World Health Organization (WHO) has published a benefit-risk assessment of Biltricide in pregnant women and women of childbearing age in areas where blood fluke infections (schistosomiasis) and worm diseases transmitted by contaminated soil are common. The report states that the benefit of Biltricide treatment outweighs the health risk to the women and their babies. The benefit of treatment in pregnant women can be seen as a reduction in the occurrence of maternal anaemia and increased birth weights as well as a higher survival rate in newborn babies. Consequently, Biltricide can be used during pregnancy if the doctor deems it necessary.
Small quantities of praziquantel are excreted in human milk. It is not known whether the medicine has an effect on the baby as a result. When receiving short-term therapy, the patient should stop breast-feeding during treatment and for a further 24 hours afterwards.
It is unknown whether Biltricide influences human fertility. In animal studies, Biltricide was not found to affect fertility.
If pregnant or breast-feeding, thinking may be pregnant or planning to have a baby, ask the doctor or pharmacist for advice before taking this medicine.